Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer

NCT03211117 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03211117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03211117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2017
Completion date
March 28, 2019
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid gland undifferentiated (anaplastic) carcinoma